Efficacy and durability of nevirapine in antiretroviral drug naïve patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 1, 2003, Pages

  Lange, Joep M A ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antiretroviral na ve; Durability; Efficacy; HIV 1 infection; Nevirapine

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ERYTHEMA; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOCHOLESTEROLEMIA; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; NAUSEA; PANCREATITIS; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; T LYMPHOCYTE; TREATMENT OUTCOME; URTICARIA; VIRUS REPLICATION; VOMITING;

CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 0141569896     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309011-00007     Document Type: Conference Paper

References (31)

1. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250:1411-3.
2. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:141-151.
3. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-545.
4. de Jong MD, Vella S, Carr A, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997;175:966-970.
5. de Jong MD, Loewenthal M, Boucher CA, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994;169:1346-50.
6. Lange JM. Current problems and the future of antiretroviral drug trials. Science 1997;276:548-50.
7. Ho D. HIV-1 dynamics in vivo. J Biol Regul Homeost Agents 1995;9:76-7.
8. Montaner JSG, Reiss P, Cooper D, et al. A randomised, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients- The INCAS trial. JAMA 1998;279:930-7.
9. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002;7:81-90.
10. Squires K. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen; final 48 week data [abstract LbPeB7046]. Presented at the 13th International AIDS Conference, Durban, 9-14 July 2000.
11. van Leeuwen R. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 2 year follow-up data [abstract MoPeB3089]. Presented at the XIV International AIDS Conference, Barcelona, Spain, 7-12 July 2002.
12. Pollard RB, Cahn P, Cassuto J, et al. Durable suppression of HIV with NVP/ZDV/3TC in treatment naïve patients with advanced disease and high baseline viral loads [abstract 1218]. Presented at the 7th European Conference on Clinical Aspects of HIV Treatment of HIV-Infection (ECCATH), Lisbon, Portugal, 23-27 October 1999.
13. Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antivir Ther 2005:267-72.
14. Garcia F, Knobel H, Sambeat MA, et al. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. AIDS 2000;14:2485-94.
15. Floridia M, Bucciardini R, Ricciardulli D, et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a non-nucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. JAIDS 1999;20:119.
16. Nunez M, Rodriguez-Rosado R, Soriano V, Gonzalez-Lahoz JM. The SENC Trial: Spanish Efavirenz vs Nevirapine Comparison Trial. Preliminary results of a prospective, randomized, controlled, open-label study in HIV+ naive individuals. Presented at the 40th Interscience Conference on Antimicrobials Agents and Chemotherapy (ICAAC); Toronto, Canada, 17-21 September 2000.
17. Kaspar R, Werntz G, Dubois D. Early results of combined stavudine, lamivudine and nevirapine: a twice-daily, well-tolerated, protease inhibitor-sparing regimen for the treatment of HIV infection [abstract 696]. Presented at the 5th Conference on Retroviruses and Opportunistic Infections (CROI), Chicago, U.S.A., 1-5 February 1998.
18. Russel D, Bal J, Anderson J, Moore R. The efficacy of nevirapine at low versus high viral loads [abstract 518]. Presented at the 7th European Conference on Clinical Aspects of HIV Treatment of HIV-Infection (ECCATH), Lisbon, Portugal, 23-27 October 1999.
19. Nelson M, Shaw A, Basar A, et al. Response of individuals with high viral loads to non-nucleoside reverse transcriptase inhibitors [abstract 518]. Presented at the 7th European Conference on Clinical Aspects of HIV Treatment of HIV-Infection (ECCATH), Lisbon, Portugal, 23-27 October 1999.
20. Chowdhury A, Skinner C, Latzke M, et al. Combination therapy with nevirapine in antiretroviral naive patients is effective in patients with high baseline viral load [abstract 106]. Presented at the 4th International Congress of Drug Therapy in HIV Infection, Glasgow, UK, 8-12 November 1998.
21. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001;285:1155-63.
22. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998;12:1619-24.
23. Raboud JM, Rae S, Montaner JS. Predicting HIV RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials. The INCAS and AVANTI Study Groups. JAIDS 2000;24:433-9.
24. van Leeuwen R, Katlama C, Murphy R, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003;17:987-99.
25. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
26. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-14.
27. van der Valk M, Kastelein J, Murphy R, et al. Nevirapine containing potent antiretroviral therapy results in a sustained antiatherogenic plasma lipid profile: 96 week results from the Atlantic Study. Presented at the 8th European Conference on Clinical Aspects of HIV Treatment of HIV-Infection (ECCATH), Athens, Greece, 28-31 October 2001.
28. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
29. Gotto Jr. AM. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation 2001;103:2213-8.
30. Boehringer Ingelheim Pharmaceuticals Inc. Viramune® (nevirapine) Prescribing Information, April 2002.
31. Pollard R. Factors predictive of durable HIV suppression in randomized double-blind trial with nevirapine (NVP) zidovudine (ZDV) and lamivudine (3TC) in treatment naïve (ARV-n) patients with advanced AIDS [poster 517]. Presented at the 7th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, U.S.A., 31 January-3 February 2000.